ZTS Zoetis Inc.

NYSE Pharmaceutical Preparations CIK: 0001555280
AI RATING
BUY
78% Confidence

Investment Thesis

Zoetis demonstrates exceptional operational profitability with 33.5% operating margins and 26.6% net margins, coupled with strong ROE of 18.6% and robust free cash flow generation. The company maintains excellent financial health with strong liquidity and solid debt service capability, though modest 2.3% revenue growth and elevated 2.80x debt/equity ratio warrant careful monitoring.

Strengths

  • + Exceptional profitability with 33.5% operating margin and 26.6% net margin
  • + Strong free cash flow generation at 12.9% FCF margin with excellent liquidity ratios (3.15x current, 1.91x quick)
  • + Superior ROE of 18.6% with EPS growth of 10.1% YoY outpacing revenue growth of 2.3%
  • + Excellent interest coverage of 12.2x providing strong debt service capability

Risks

  • ! Modest revenue growth of 2.3% YoY raises sustainability and competitive positioning concerns
  • ! Elevated debt-to-equity ratio of 2.80x represents significant financial leverage
  • ! Operating cash flow of $401M appears low relative to $15.2B asset base indicating capital intensity

Key Metrics to Watch

Financial Metrics

Revenue
2.3B
Net Income
601.0M
EPS (Diluted)
$1.42
Free Cash Flow
291.0M
Total Assets
15.2B
Cash
1.9B

Profitability Ratios

Gross Margin N/A
Operating Margin 33.5%
Net Margin 26.6%
ROE 18.6%
ROA 4.0%
FCF Margin 12.9%

Balance Sheet & Liquidity

Current Ratio
3.15x
Quick Ratio
1.91x
Debt/Equity
2.80x
Debt/Assets
78.7%
Interest Coverage
12.23x
Long-term Debt
9.0B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-09T14:06:29.615637 | Data as of: 2026-03-31 | Powered by Claude AI